Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (WO2017207820) POLYTHÉRAPIE COMPRENANT UNE CÉTONE POLYINSATURÉE ET UN PARTENAIRE D'ACIDE FOLIQUE
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

What is claimed is:

1. A pharmaceutical composition comprising:

(A) at least one compound of formula (I):


wherein R is a C10-24 unsaturated hydrocarbon group optionally interrupted by one or more heteroatoms or groups of heteroatoms selected from S, O, N, SO, S02, said hydrocarbon group comprising at least 4 non-conjugated double bonds;

L is a linking group forming a bridge of 1 to 5 atoms between the R group and the carbonyl CO wherein L comprises at least one heteroatom in the backbone of the linking group; and

X is an electron withdrawing group;

or a pharmaceutically acceptable salt, or a hydrate or solvate thereof; and

(B) at least one folic acid partner selected from methotrexate, folic acid or arninopterin, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof, especially methotrexate or arninopterin or a pharmaceutically acceptable salt, or a hydrate or solvate thereof.

2. The pharmaceutical composition of claim 1 wherein the composition is a fixed combination or non-fixed combination

3. A pharmaceutical composition as claimed in claim 1 for simultaneous, parallel, equential or separate use comprising a kit comprising a first composition comprising at east one compound (I) as defined in claim 1 and a pharmaceutically-acceptable diluent or arrier, and a second composition comprising at least one compound (B) as defined in laim 1 and a pharmaceutically-acceptable diluent or carrier.

. A composition as claimed in any preceding claim wherein the compound (B) is methotrexate, or arninopterin, preferably methotrexate or a pharmaceutically acceptable alt, or a hydrate or solvate thereof.

5. A composition as claimed in any preceding claim wherein the compound (B) is methotrexate or a pharmaceutically acceptable salt, or a hydrate or a solvate thereof.

6. A composition as claimed in any preceding claim wherein the compound (B) is methotrexate hydrate.

7. A composition as claimed in any preceding claim wherein in formula (I), the group X is CHal3, preferably CF3.

8. A composition as claimed in any preceding claim wherein in formula (I), the group R is a linear unsubstituted C10-24 unsaturated alkylene group comprising at least 4 non-conjugated double bonds.

A composition as claimed in any preceding claim wherein L is -SCH2-

10. A composition as claimed in any preceding claim wherein said compound of formula (I) has the formula:

wherein X is as defined in claim 1, e.g. CF3.

11. A composition as claimed in any preceding claim where the compound of formula (I) is Compound Al or Compound A2:

especially when compound (B) is methotrexate or aminopterin or a salt, hydrate or solvate thereof.

12. A composition as claimed in any preceding claim wherein the molar ratio of compound (A) to (B) in the composition is 10:1 to 1:10, preferably 1:5 to 5:1.

13. A pharmaceutical composition as claimed in claim 1 to 13 for use in the treatment or prevention of a skin disorder such as psoriasis or dermatitis.

4. A method of treating, such as reducing symptoms of, or preventing a skin disorder uch as psoriasis or dermatitis in a patient in need thereof comprising administering to aid patient, preferably a human, an effective amount of a composition as claimed in claim 1 to 12.

5. A method of treating, such as reducing symptoms of, or preventing a skin disorder uch as psoriasis or dermatitis in a patient in need thereof comprising administering to aid patient, preferably a human, an effective amount of a compound of formula (I) as defined in claim 1 to 12 and simultaneously, separately or sequentially administering to aid patient a compound (B) as defined in claim 1 to 12.

6. A method of treating such as, reducing symptoms of, or preventing a skin disorder uch as psoriasis or dermatitis, in a patient in need thereof comprising:

(i) identifying a patient who has received either a compound of formula (I) or a compound (B) as defined in claim 1 to 12 respectively;

(ii) administering to said patient an effective amount of either at least one compound (B) or at least one compound of formula (I) as defined in claim 1 to 12 so that said patient is administered with both a compound of formula (I) and a compound (B).

17. A method of treating, such as reducing symptoms of, or preventing a skin disorder such as psoriasis or dermatitis in an animal subject in need thereof comprising administering to said animal an effective amount of a composition or as claimed in claim l to l2.

18. A method of treating, such as reducing symptoms of, or preventing a skin disorder such as psoriasis or dermatitis in an animal subject in need thereof comprising administering to said animal an effective amount of at least one compound of formula (I) as defined in claim 1 to 12 and simultaneously, in parallel, separately or sequentially administering to said animal at least one compound (B) as defined in claim 1 to 12.

19. The method of claim 17 or 18, wherein the animal subject is a rodent, monkey, or a pig.

20. The method of claim 18 or 19, wherein the pharmaceutical composition or the effective amount of compound of Formula I and compound B is used as a positive control.

21. Use of a composition as claimed in claim 1 to 12 in the manufacture of a medicament for treating or preventing a skin disorder such as psoriasis or dermatitis.

22. The pharmaceutical composition product of any of claims 1 to 12 comprising methotrexate or aminopterin or a salt, hydrate or solvate thereof optionally in

combination with one or more additional folic acid partners.

23. A pharmaceutical composition or as claimed in any one of claims 1 to 12 in a form suitable for topical administration, e.g. a cream, gel, foam or ointment.